Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer.
Exceptional response
Immunotherapy
Metaplastic breast cancer
Program death ligand-1
Journal
Case reports in oncology
ISSN: 1662-6575
Titre abrégé: Case Rep Oncol
Pays: Switzerland
ID NLM: 101517601
Informations de publication
Date de publication:
Historique:
received:
04
02
2021
accepted:
26
02
2021
entrez:
12
7
2021
pubmed:
13
7
2021
medline:
13
7
2021
Statut:
epublish
Résumé
Metaplastic breast cancer (MBC) is a rare and aggressive subtype of breast cancer. Tumor characteristics typically feature estrogen receptor, progesterone receptor, and HER2-negative, triple-negative breast cancer (TNBC), with a poorer prognosis relative to pure invasive ductal or lobular disease. Resistance to chemotherapy often leads to local recurrence and distant metastasis. Genomic profiling has identified multiple molecular abnormalities that may translate to targetable therapies in MBC. These tumors are known to display higher PD-L1 expressivity than other subtypes of breast cancer, and disease control with pembrolizumab and chemotherapy has been documented. We identify a patient with metastatic, metaplastic TNBC, with mesenchymal components and osseous differentiation, who completed 2 years of pembrolizumab treatment and has remained without evidence of disease after 32 months of observation, while maintaining good quality of life. Future efforts should focus on immunotherapy response with respect to the various subtypes of MBC, and treatment should continue to be incorporated in clinical trials to maximize disease response.
Identifiants
pubmed: 34248561
doi: 10.1159/000515510
pii: cro-0014-0931
pmc: PMC8255711
doi:
Types de publication
Case Reports
Langues
eng
Pagination
931-937Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Informations de copyright
Copyright © 2021 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
NPJ Breast Cancer. 2017 Mar 29;3:8
pubmed: 28649648
Clin Cancer Res. 2018 Jun 15;24(12):2804-2811
pubmed: 29559561
Clin Breast Cancer. 2017 Feb;17(1):e1-e10
pubmed: 27568101
J Clin Pathol. 2017 Mar;70(3):255-259
pubmed: 27531819
J Natl Cancer Inst. 2016 Dec 31;109(6):
pubmed: 28040796
Am J Case Rep. 2019 Nov 06;20:1630-1635
pubmed: 31690713
Curr Oncol Rep. 2015 Mar;17(3):431
pubmed: 25691085
Am J Surg Pathol. 2017 Mar;41(3):334-342
pubmed: 28195880
Clin Breast Cancer. 2016 Dec;16(6):437-443
pubmed: 27431460
Breast Cancer Res Treat. 2017 Oct;165(3):499-504
pubmed: 28689362
Cancer Treat Rev. 2019 Sep;79:101888
pubmed: 31491663
J Clin Oncol. 2016 Jul 20;34(21):2460-7
pubmed: 27138582
Ann Oncol. 2015 Jul;26(7):1346-52
pubmed: 25878190
NPJ Breast Cancer. 2017 Dec 1;3:48
pubmed: 29214215
Arch Pathol Lab Med. 2015 May;139(5):642-9
pubmed: 25927147